EA200970656A1 - Вич-ингибирующие 5,6-замещенные пиримидины - Google Patents

Вич-ингибирующие 5,6-замещенные пиримидины

Info

Publication number
EA200970656A1
EA200970656A1 EA200970656A EA200970656A EA200970656A1 EA 200970656 A1 EA200970656 A1 EA 200970656A1 EA 200970656 A EA200970656 A EA 200970656A EA 200970656 A EA200970656 A EA 200970656A EA 200970656 A1 EA200970656 A1 EA 200970656A1
Authority
EA
Eurasian Patent Office
Prior art keywords
6alkyl
cyano
amino
6alkynyl
het
Prior art date
Application number
EA200970656A
Other languages
English (en)
Other versions
EA020749B1 (ru
Inventor
Жером Эмиль Жорж Гийемон
Селин Изабелль Мордан
Бенуа Антуан Шмитт
Original Assignee
Тиботек Фармасьютикалз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тиботек Фармасьютикалз Лтд. filed Critical Тиботек Фармасьютикалз Лтд.
Publication of EA200970656A1 publication Critical patent/EA200970656A1/ru
Publication of EA020749B1 publication Critical patent/EA020749B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Rозначает атом водорода; арил; формил; Cалкилкарбонил; Cалкил; Cалкилоксикарбонил; R, R, Rи Rозначают атом водорода; гидрокси; атом галогена; Сциклоалкил; Cалкилокси; карбоксил; Cалкилоксикарбонил; циано; нитро; амино; моно- или ди(Cалкил)амино; полигалогенСалкил; полигалогенСалкилокси; -C(=O)R; Cалкил, необязательно замещенный атомом галогена, цианогруппой или -C(=O)R; необязательно замещенный Cалкил, Салкенил или Салкинил; Rи Rозначают гидрокси; атом галогена; Сциклоалкил; Cалкилокси; карбоксил; Cалкилоксикарбонил; формил; циано; нитро; амино; моно- или ди(Cалкил)амино; полигалогенСалкил; полигалогенСалкилокси; -C(=O)R; циано; -S(=O)R; -NH-S(=O)R; -NHC(=O)H; -C(=O)NHNH; -NHC(=O)R; Het; -Y-Het; необязательно замещенный Cалкил, Cалкенил или Cалкинил; Rозначает С-алкенил или Салкинил, оба замещенные цианогруппой, аминокарбонильной, моно- или ди(Cалкил)аминокарбонильной, арильной, пиридильной, тиенильной, фуранильной или одной или двумя Cалкилоксигруппами; Het; -С(=O)NRR; -СН(OR)R; X означает -NR-, -О-, -CH- или -S-; фармацевтические композиции, содержащие указанные соединения в качестве активного ингредиента, и способы получения указанных соединений и композиций.
EA200970656A 2006-12-29 2007-12-28 Вич-ингибирующие 5,6-замещенные пиримидины EA020749B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06127328 2006-12-29
PCT/EP2007/064606 WO2008080965A2 (en) 2006-12-29 2007-12-28 Hiv inhibiting 5,6-substituted pyrimidines

Publications (2)

Publication Number Publication Date
EA200970656A1 true EA200970656A1 (ru) 2009-12-30
EA020749B1 EA020749B1 (ru) 2015-01-30

Family

ID=39310923

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200970656A EA020749B1 (ru) 2006-12-29 2007-12-28 Вич-ингибирующие 5,6-замещенные пиримидины

Country Status (12)

Country Link
US (1) US8318736B2 (ru)
EP (2) EP2114902B1 (ru)
JP (1) JP5283633B2 (ru)
KR (1) KR20090094084A (ru)
CN (2) CN106045965A (ru)
AU (1) AU2007341228B2 (ru)
BR (1) BRPI0722079B8 (ru)
CA (2) CA2674185C (ru)
EA (1) EA020749B1 (ru)
ES (2) ES2523863T3 (ru)
MX (1) MX2009007006A (ru)
WO (1) WO2008080965A2 (ru)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007003796A (es) 2004-09-30 2007-04-25 Tibotec Pharm Ltd Pirimidinas 5-sustituidas inhibidoras del virus de inmunodeficiencia humana.
RU2405778C2 (ru) 2004-09-30 2010-12-10 Тиботек Фармасьютикалз Лтд. 5-гетероциклилпиримидины, ингибирующие вич
EP1951715B1 (en) * 2005-11-03 2013-09-04 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
CA2645958C (en) 2006-03-30 2014-11-04 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-amido substituted pyrimidines
CA2674178C (en) * 2006-12-29 2015-11-10 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 6-substituted pyrimidines
AU2009244897B2 (en) 2008-04-16 2014-11-13 Alexion Pharmaceuticals, Inc. 2, 6-diamino- pyrimidin- 5-yl-carboxamides as syk or JAK kinases inhibitors
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
LT2300013T (lt) 2008-05-21 2017-12-27 Ariad Pharmaceuticals, Inc. Fosforo dariniai kaip kinazių inhibitoriai
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
NZ624345A (en) 2008-06-27 2016-07-29 Celgene Avilomics Res Inc 2,4-disubstituted pyrimidines useful as kinase inhibitors
TW201010984A (en) 2008-07-29 2010-03-16 Boehringer Ingelheim Int 5-alkynyl-pyrimidines
TW201020245A (en) * 2008-08-20 2010-06-01 Schering Corp Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
AU2009282574B2 (en) * 2008-08-20 2014-08-21 Merck Sharp & Dohme Corp. Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
EP2440559B1 (en) 2009-05-05 2018-01-10 Dana-Farber Cancer Institute, Inc. Egfr inhibitors and methods of treating disorders
UY33198A (es) 2010-01-26 2011-08-31 Boehringer Ingelheim Int 5-alquinil-pirimidinas.
US8633183B2 (en) 2010-01-26 2014-01-21 Boehringer Ingelheim International Gmbh 5-alkynyl-pyrimidines
CN105566229A (zh) 2010-08-10 2016-05-11 西建阿维拉米斯研究公司 Btk抑制剂的苯磺酸盐及其用途和制备方法
US9238629B2 (en) 2010-11-01 2016-01-19 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2012061299A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heterocyclic compounds and uses thereof
US8796255B2 (en) 2010-11-10 2014-08-05 Celgene Avilomics Research, Inc Mutant-selective EGFR inhibitors and uses thereof
US9126949B2 (en) 2011-04-25 2015-09-08 Hetero Research Foundation Process for rilpivirine
CN103501612B (zh) 2011-05-04 2017-03-29 阿里亚德医药股份有限公司 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物
CA2853498A1 (en) 2011-10-28 2013-05-02 Celgene Avilomics Research, Inc. Methods of treating a bruton's tyrosine kinase disease or disorder
JP6039683B2 (ja) 2011-11-23 2016-12-07 ポートラ ファーマシューティカルズ, インコーポレイテッド ピラジンキナーゼ阻害剤
SI2825042T1 (sl) 2012-03-15 2019-01-31 Celgene Car Llc Soli inhibitorja kinaze receptorja faktorja epidermalne rasti
WO2013138495A1 (en) 2012-03-15 2013-09-19 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2014124230A2 (en) 2013-02-08 2014-08-14 Celgene Avilomics Research, Inc. Erk inhibitors and uses thereof
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
CN103483272B (zh) * 2013-09-29 2015-10-21 山东大学 间二芳烃-多取代嘧啶类衍生物及其制备方法与应用
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
DK3179858T3 (da) 2014-08-13 2019-07-22 Celgene Car Llc Forme og sammensætninger af en ERK-inhibitor
CN106967047A (zh) * 2017-03-29 2017-07-21 山东大学 一种取代二芳基烟酰胺类衍生物及其制备方法与应用
JP6545746B2 (ja) * 2017-05-09 2019-07-17 山田化学工業株式会社 色素化合物
DE102017004596B4 (de) * 2017-05-13 2021-02-11 Alzchem Trostberg Gmbh Verfahren zur Herstellung von Phenylguanidinen oder deren Salze
CN111285859B (zh) * 2020-04-02 2021-07-02 山东大学 一类以hiv-1逆转录酶为靶点的2,4,5-三取代嘧啶类化合物及其制备方法与应用
CN111560013B (zh) * 2020-06-08 2023-04-07 中山大学 一种自噬抑制剂及其应用
CN111875548A (zh) * 2020-07-16 2020-11-03 山东大学 一种5位芳环取代的二芳基嘧啶类衍生物及其制备方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3459731A (en) * 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
SK67298A3 (en) 1995-11-23 1998-11-04 Janssen Pharmaceutica Nv Solid mixtures of cyclodextrins prepared via melt-extrusion
NO311614B1 (no) * 1996-10-01 2001-12-17 Janssen Pharmaceutica Nv Substituerte diamino-1,3,5-triazinderivater
SI0945443T1 (en) 1998-03-27 2003-08-31 Janssen Pharmaceutica N.V. HIV inhibiting pyrimidine derivatives
EP0945447A1 (en) 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
NZ511116A (en) 1998-11-10 2003-08-29 Janssen Pharmaceutica Nv HIV replication inhibiting pyrimidines
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
AU783981C (en) * 2000-05-08 2007-05-03 Janssen Pharmaceutica N.V. HIV replication inhibitors
MXPA03005610A (es) * 2000-12-21 2003-10-06 Vertex Pharma Compuestos de pirazol utiles como inhibidores de la proteina cinasa.
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
AR039540A1 (es) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd Compuestos microbicidas con contenido de pirimidina o triazina
WO2004046143A1 (en) 2002-11-15 2004-06-03 Tibotec Pharmaceuticals Ltd. Substituted indolepyridinium as anti-infective compounds
CL2004000303A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
US7504396B2 (en) * 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
MX2007003796A (es) * 2004-09-30 2007-04-25 Tibotec Pharm Ltd Pirimidinas 5-sustituidas inhibidoras del virus de inmunodeficiencia humana.
RU2405778C2 (ru) 2004-09-30 2010-12-10 Тиботек Фармасьютикалз Лтд. 5-гетероциклилпиримидины, ингибирующие вич
WO2006035068A2 (en) * 2004-09-30 2006-04-06 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-carbo- or heterocyclic substituted pyrimidines
WO2006079656A1 (en) * 2005-01-27 2006-08-03 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 2-( 4-cyanophenylamino) pyrimidine derivatives
CA2645958C (en) 2006-03-30 2014-11-04 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 5-amido substituted pyrimidines
CA2674178C (en) * 2006-12-29 2015-11-10 Tibotec Pharmaceuticals Ltd. Hiv inhibiting 6-substituted pyrimidines

Also Published As

Publication number Publication date
ES2618057T3 (es) 2017-06-20
US20100261722A1 (en) 2010-10-14
BRPI0722079B8 (pt) 2021-05-25
BRPI0722079B1 (pt) 2020-01-14
JP2010514736A (ja) 2010-05-06
CA2674185A1 (en) 2008-07-10
CA2923637C (en) 2018-10-02
CA2923637A1 (en) 2008-07-10
EP2114902B1 (en) 2014-09-17
CA2674185C (en) 2017-02-28
WO2008080965A2 (en) 2008-07-10
AU2007341228A1 (en) 2008-07-10
EP2781510B1 (en) 2016-12-14
AU2007341228B2 (en) 2013-04-18
EA020749B1 (ru) 2015-01-30
EP2114902A2 (en) 2009-11-11
ES2523863T3 (es) 2014-12-02
CN106045965A (zh) 2016-10-26
CN101573342A (zh) 2009-11-04
US8318736B2 (en) 2012-11-27
MX2009007006A (es) 2009-07-09
KR20090094084A (ko) 2009-09-03
EP2781510A1 (en) 2014-09-24
BRPI0722079A2 (pt) 2014-04-08
JP5283633B2 (ja) 2013-09-04
WO2008080965A3 (en) 2008-09-04

Similar Documents

Publication Publication Date Title
EA200970656A1 (ru) Вич-ингибирующие 5,6-замещенные пиримидины
EA200970655A1 (ru) 6-замещенные пиримидины, ингибирующие вич
NZ603896A (en) 3-amino-5,6-dihydro-1h-pyrazin-2-one derivatives useful for the treatement of alzheimer's disease and other forms of dementia
RU2008143001A (ru) 5-амидозамещенные пиримидины, ингибирующие вич
MX344669B (es) Agente antiplaquetas novedoso.
RU2008143018A (ru) 5(гидроксиметилен-и аминометилен)замещенные пиримидины, ингибирующие вич
NO20050418L (no) Kondenserte pyridiner og pyrimidiner med TIE2(TEK) aktivitet
MX2009004920A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1.
MX2014000359A (es) Metodos plaguicidas que utilizan compuestos de 3 - piridin tiazol sustituido y derivados para combatir las plagas de animales ii.
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
JP2014525420A5 (ru)
NZ599040A (en) 2,4-disubstituted pyrido[4,3-d]pyrimidin-5(6h)-one compounds for selective inhibitors of lrrk2 and syk kinases
NO20091409L (no) Pyridin-3-yl-derivater som immunmodulerende midler
JP2011522866A5 (ru)
ATE556058T1 (de) 1-(2h)-isochinolonderivat
NO20091394L (no) Pyridin-4-yl-derivater som immunmodulerende midler
WO2009156861A8 (en) Substituted pyrimidone derivatives
UY30897A1 (es) Derivados de pentafluorotiobenzamidoacetonitrilo, composiciones conteniéndolos y aplicaciones
MX344276B (es) Compuesto de piperidina novedoso o sal del mismo.
WO2006065590A3 (en) Pyridine and pyrimidine antiviral compositions
TW200612920A (en) Novel imidazolidine derivatives
WO2010089510A3 (fr) Dérivés d'azaspiranyl-alkylcarbamates d'hétérocycles à 5 chaînons, leur préparation et leur application en thérapeutique
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
MX339668B (es) Compuestos de piridil amida sustituidos como moduladores del receptor h3 de la histamina.
TW200728298A (en) Thiophene compounds and thrombopoietin receptor activators

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
TC4A Change in name of a patent proprietor in a eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG MD TJ TM